Concepedia

S. Griffing

SG

Statistics

Publications

5

Citations

12.8K

H-Index

5

Active since

2002

Affiliations

Duke University(Current)

S. Griffing is an author at Duke University specializing in medicine, oncology, and cancer pharmacology.

Publications per year

2002–2005

5

Publications

5

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Herbert I. Hurwitz, Louis Fehrenbacher, William Novotny et al. · New England Journal of Medicine · 2004 · 11K citations · Full text

Medicine, Oncology, Pharmacology +15

Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer

Fairooz F. Kabbinavar, Herbert I. Hurwitz, Louis Fehrenbacher et al. · Journal of Clinical Oncology · 2002 · 1.7K citations

Medicine, Oncology, Pharmacotherapy +13

Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies

H. S. Hochster, Lauri Welles, L. Hart et al. · Journal of Clinical Oncology · 2005 · 58 citations

Medicine, Oncology, Pharmacology +12

Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer (CRC) in subjects who are not suitable candidates for first-line CPT-11

Fairooz F. Kabbinavar, J Schulz, Michael McCleod et al. · Journal of Clinical Oncology · 2004 · 34 citations

Medicine, Oncology, Pharmacotherapy +11

Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC)

Eric Hedrick, Herbert I. Hurwitz, Somnath Sarkar et al. · Journal of Clinical Oncology · 2004 · 31 citations

Medicine, Oncology, Pharmacology +16

1–5 of 5